Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Absci
About
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
- Vancouver,Washington,United States
- 101 - 250
- https://www.absci.com
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $12M
- Industries
- Artificial Intelligence,Biopharma,Biotechnology,Life Science
- Founded date
- Jan 1, 2011
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:ABSI
- Legal Name
- Absci Corp.
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 21, 2021 | IPO | $200M | — | — | — | Detail |
| Mar 23, 2021 | Series Unknown | $125M | 9 |
Casdin Capital
|
— | Detail |
| Feb 22, 2021 | Corporate Round | — | 1 |
Merck Global Health Innovation Fund
|
— | Detail |
| Oct 20, 2020 | Series E | $69.99M | 4 |
Casdin Capital
|
— | Detail |
| Jan 14, 2020 | Series D | $10.40M | 6 |
JSR Life Sciences
KBI Biopharma
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 19, 2022
Ambient.ai
|
Series Unknown | $52M | Artificial Intelligence | — |
|
Jan 14, 2021
X1
|
Series A | $12M | Credit Cards | — |
|
Nov 6, 2019
Digits
|
Series A | $10.50M | Artificial Intelligence | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Casdin Capital
|
Yes | Series Unknown |
|
|
Yes | Series Unknown |
|
Merck Global Health Innovation Fund
|
Yes | Corporate Round |
|
JSR Life Sciences
|
Yes | Series D |
|
KBI Biopharma
|
Yes | Series D |
|
|
Yes | Series D |
AGC
|
Yes | Series C |
aMoon Fund
|
— | Series Unknown |
ArrowMark Partners
|
— | Series Unknown |
D1 Capital Partners
|
— | Series Unknown |
Employee Profiles
Acquisition
Absci has acquired 2 organizations. Their most recent acquisition was Denovium on Jan 12, 2021. They acquired Denovium for 0.
